Review Article

Pentraxin 3 as a Prognostic Biomarker in Patients with Systemic Inflammation or Infection

Table 2

Patients characteristics of the included studies.

First authorReferencesCriteria used for diagnosisDiagnosis on admission as described by the authors (no. of patients)Period

Muller[15]SIRS, sepsis, severe sepsis, and septic shock criteriaSepsis, severe sepsis, or septic shock (33) SIRS (68)September 1996 to June 1997

Mauri[18]ALI/ARDS criteria
SIRS, septic, severely septic or septic shock criteria
ALI/ARDS (21)
Nonseptic (3), SIRS (4), septic (0), severely septic (5), septic shock (9)
January 2005 to October 2006

Sprong[19]Meningococcal diseasemeningococcal disease (26)1994 to 2004

Mauri[20]Severe sepsis or septic shock criteriaSevere sepsis (18), septic shock (72)December 2004 to March 2007

de Kruif[21]Fever criteria, bacteremia criteriaFebrile patients (211), bacteremia (35)April 2004 to October 2006, one month follow-up after enrollment

Huttunen[22]Blood culture positive for S. aureus, S. pneumoniae, β-hemolytic Streptococcus or E. coliBacteremia (132)June 1999 to February 2004

Vänskä[23]Neutropenic fever and septic chock criteriaNeutropenic fever (100), septic shock (5)December 2006 to December 2009

Bastrup-Birk[24]SIRS criteriaSIRS (261)Undefined, median follow up time 873 (range, 0–1458) days

Uusitalo-Seppälä[25]Suspected infection : Bacterial infection, SIRS, Sepsis and Severe sepsis criteria Suspected infection (537) : Bacterial infection (67), SIRS (54), Sepsis (308), severe sepsis (49)2004 to 2005, 14 months, one year
follow-up after enrollment

Lin[26]VAP criteriaVAP (86)January 2010 to December 2011, 28 days follow-up after enrollment

Kao [27]CAP criteriaCAP (61)January 2009 to December 2009